Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin M Balko

Showing results (41-50 of 174) with videos related to

Pageof 18
Sort By:
NPJ Genomic Medicine|December 22, 2017
A prognostic signature based on three-genes expression in triple-negative breast tumours with residual diseaseJoseph A Pinto, Jhajaira Araujo, Nadezhda K Cardenas, et al.
British Journal of Clinical Pharmacology|June 17, 2020
Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapyBrendan L Mangan, Renee K McAlister, Justin M Balko, et al.
AAPS Pharmscitech|April 22, 2009
Intratumoral delivery of Paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulationsAbeer M Al-Ghananeem, Ahmad H Malkawi, Yahya M Muammer, et al.
The Journal of Biological Chemistry|June 28, 2020
Correction: Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signalingYou-Take Oh, Ping Yue, Wei Zhou, et al.
The Journal of Biological Chemistry|November 9, 2011
Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signalingYou-Take Oh, Ping Yue, Wei Zhou, et al.
Molecular & Cellular Proteomics : MCP|April 19, 2017
WITHDRAWN: Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanomaCarlos A Morales-Betanzos, Hyoungjoo Lee, Paula I Gonzalez-Ericsson, et al.
JCO Precision Oncology|September 11, 2020
Clinical Response to Anti-Programmed Death 1 After Response and Subsequent Progression on Anti-Programmed Death Ligand 1 TherapyEmily H Castellanos, Emily Feld, Monica V Estrada, et al.
Molecular & Cellular Proteomics : MCP|May 27, 2017
Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, <i>N</i>-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human MelanomaCarlos A Morales-Betanzos, Hyoungjoo Lee, Paula I Gonzalez Ericsson, et al.
The Lancet. Oncology|August 8, 2020
Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and researchDouglas B Johnson, Kerry L Reynolds, Ryan J Sullivan, et al.
The Oncologist|April 3, 2019
Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 TherapyHenry T Quach, Charles J Robbins, Justin M Balko, et al.
Pageof 18

Showing results (41-50 of 174) with videos related to

Sort By:
Pageof 18
NPJ Genomic Medicine|December 22, 2017
A prognostic signature based on three-genes expression in triple-negative breast tumours with residual diseaseJoseph A Pinto, Jhajaira Araujo, Nadezhda K Cardenas, et al.
British Journal of Clinical Pharmacology|June 17, 2020
Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapyBrendan L Mangan, Renee K McAlister, Justin M Balko, et al.
AAPS Pharmscitech|April 22, 2009
Intratumoral delivery of Paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulationsAbeer M Al-Ghananeem, Ahmad H Malkawi, Yahya M Muammer, et al.
The Journal of Biological Chemistry|June 28, 2020
Correction: Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signalingYou-Take Oh, Ping Yue, Wei Zhou, et al.
The Journal of Biological Chemistry|November 9, 2011
Oncogenic Ras and B-Raf proteins positively regulate death receptor 5 expression through co-activation of ERK and JNK signalingYou-Take Oh, Ping Yue, Wei Zhou, et al.
Molecular & Cellular Proteomics : MCP|April 19, 2017
WITHDRAWN: Quantitative mass spectrometry analysis of PD-L1 protein expression, N-glycosylation and expression stoichiometry with PD-1 and PD-L2 in human melanomaCarlos A Morales-Betanzos, Hyoungjoo Lee, Paula I Gonzalez-Ericsson, et al.
JCO Precision Oncology|September 11, 2020
Clinical Response to Anti-Programmed Death 1 After Response and Subsequent Progression on Anti-Programmed Death Ligand 1 TherapyEmily H Castellanos, Emily Feld, Monica V Estrada, et al.
Molecular & Cellular Proteomics : MCP|May 27, 2017
Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, <i>N</i>-glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human MelanomaCarlos A Morales-Betanzos, Hyoungjoo Lee, Paula I Gonzalez Ericsson, et al.
The Lancet. Oncology|August 8, 2020
Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and researchDouglas B Johnson, Kerry L Reynolds, Ryan J Sullivan, et al.
The Oncologist|April 3, 2019
Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 TherapyHenry T Quach, Charles J Robbins, Justin M Balko, et al.
Pageof 18